A Study to Compare Model Predictive Control (MPC) Artificial Pancreas vs. Sensor Augmented Pump (SAP)/Predictive Low Glucose Suspend (PLGS) with Different Stress Assessments for Type 1 Diabetes Patients


About this study

The purpose of this study is to compare the effectiveness and safety of an automated insulin delivery (AID) system using a model predictive control (MPC) algorithm versus Sensor-Augmented Pump/Predictive Low Glucose Suspend (SAP/PLGS) therapy with different stress assessments over a 4-week period.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Clinical diagnosis, based on investigator assessment, of type 1 diabetes for at least one.
  • Year and using insulin for at least 1 year.
  • Using an insulin pump for at least 3 months at the time of screening.
  • Insulin pump use includes use of automated features, to include predictive or threshold low-glucose suspend or hybrid closed-loop with or without a Dexcom sensor.
  • Familiarity and use of a carbohydrate ratio for meal boluses.
  • Age ≥ 18.0 years old.
  • HbA1c < 10.5%, as performed by point of care or central 513 laboratory testing. A1c will be 514 assessed at the screening visit, or if already completed within 2 weeks of the screening visit, the prior lab value may be used in lieu of repeating this assessment.
  • For females, not currently known to be pregnant.
  • If female and sexually active, must agree to use a form of contraception to prevent pregnancy while a participant in the study and up to one month afterwards. A negative serum or urine pregnancy test will be required for all females of child-bearing potential. Participants who become pregnant will be discontinued from the study. Also, participants who during the study develop and express the intention to become pregnant within the timespan of the study will be discontinued.
  • Willingness to switch home pump to PLGS or full manual mode if using hybrid closed loop with an FDA approved system.
  • Investigator has confidence that the participant can successfully operate all study devices and is capable of adhering to the protocol.
  • Willingness to switch to lispro (Humalog) or aspart (Novolog) if not using already, and to use no other insulin besides lispro (Humalog) or aspart (Novolog) during the study.
  • Willingness not to start any new non-insulin glucose-lowering agent during the course of the trial

Exclusion Criteria:

  • Use of an unapproved closed-loop insulin delivery system within 2 weeks before screening or during the study is not allowed.
  • Have a blood pressure at screening outside the range of 160 mmHg systolic blood pressure and/or greater than 100 mmHg for diastolic blood pressure (if repeated measurements are within this range, the patient may be included in the study).
  • Have coronary artery disease that is not stable with medical management, including unstable angina, angina that prevents moderate exercise despite medical management, or within the last 12 months before screening a history of myocardial infarction, percutaneous coronary intervention, enzymatic lysis of a presumed coronary occlusion, or coronary artery bypass grafting.
  • Concurrent use of Afrezza or any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, SGLT-2 inhibitors, sulfonylureas).
  • Hemophilia or any other bleeding disorder.
  • A condition, which in the opinion of the investigator or designee, would put the participant or study at risk, to include:
    • Pregnancy, or planning pregnancy within 1 month of completing the clinical trial;
    • Allergy or hypersensitivity to hydrocortisone, or any component of the formulation;
    • Presence of a known adrenal disorder;
    • Systemic fungal infections;
    • Active infection of any kind, or at risk of infection (susceptibility to infection) from known immunosuppression or underlying immunosuppressed condition;
    • Idiopathic thrombocytopenia purpura (ITP);
    • Varicella;
    • Glaucoma or other chronic ocular condition that could be adversely affected by steroids (e.g., cataracts, increased ocular pressure from other causes, exophthalmos);
    • Hypertension requiring treatment with one or more antihypertensive medications;
    • Congestive heart failure;
    • Current treatment for a seizure disorder;
    • Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation, including subjects not able to read or write;
    • Known coronary artery disease;
    • Active gastroparesis;
    • Cystic fibrosis;
    • Uncontrolled thyroid disease (TSH undetectable or > 10 mIU/L);
    • Known abuse of alcohol;
    • A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the protocol;
    • Current use of a beta blocker medication;
    • Laboratory results:
      • A1C > 10.5%
      • Abnormal liver or renal function (Transaminase >2 times the upper limit of normal, creatinine> 1.5 mg/dL);
      • Labs drawn at screening visit or within three months prior to screening (for other purposes) will suffice for enrollment purposes.
  • Subject has skin conditions that, in the determination of the investigator, would preclude wearing the study devices (infusion set and sensor), in the abdomen.
  • Examples include but are not limited to: psoriasis, burns, scaring, eczema, tattoos, and significant hypertrophy at sites of device wear; any known allergy to medical adhesives.
  • Currently on long-term treatment 586 using prednisone or other steroid.
  • If subject had been on short term treatment of prednisone, defer enrollment until underlying condition and prednisone treatment have resolved.
  • Allergy to study drug, food or other study material.
  • Clinically significant physical examination, laboratory test, or vital sign abnormality.
  • Exposure to any investigational drug within 30 days.
  • History of malignancy within the 5 years before screening (other than basal cell carcinoma).
  • Participation in another pharmaceutical or device trial at the time of enrollment or during the study.
  • Having a direct supervisor at place of employment who is also directly involved in conducting the clinical trial (as a study investigator, coordinator, etc.); or having a first degree relative who is directly involved in conducting the clinical trial.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Yogish Kudva, M.B.B.S.

Closed for enrollment

Contact information:

Shelly McCrady-Spitzer M.S.



More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer